Company intelligence / Profile preview

PolyGene

Rumlang, Zurich, Switzerlandpolygene.ch ↗

Ownership: Private
Development stage: Commercial

Overview

PolyGene specializes in the rapid generation of genetically modified rodent models—primarily mice and rats—using advanced genome editing techniques such as CRISPR. These custom animal models are used by pharmaceutical companies and academic researchers to validate drug targets, study disease mechanisms, and support preclinical development.

Modalities: Gene therapyCRISPR-based therapyTransgenic animal models
Industry: Non-Drug Biotech

Partnerships

Pharmaceutical companiesAcademic institutions

Beyond the preview

Go deeper on PolyGene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PolyGene.

Explore the full profile